Drug Profile
Research programme: overactive bladder therapies - Ferring Pharmaceuticals
Alternative Names: FE 106 486Latest Information Update: 22 Feb 2010
Price :
$50
*
At a glance
- Originator Ferring Pharmaceuticals
- Class
- Mechanism of Action G protein-coupled receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Overactive bladder
Most Recent Events
- 22 Feb 2010 Discontinued - Preclinical for Overactive bladder in Switzerland (PO)
- 12 Jul 2007 Preclinical trials in Overactive bladder in Switzerland (PO)